Lexicon Pharmaceuticals Inc (LXRX) concluded trading on Wednesday at a closing price of $0.84, with 10.16 million shares of worth about $8.53 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -57.79% during that period and on January 22, 2025 the price saw a gain of about 6.56%. Currently the company’s common shares owned by public are about 361.49M shares, out of which, 168.72M shares are available for trading.
Stock saw a price change of 21.40% in past 5 days and over the past one month there was a price change of 24.04%. Year-to-date (YTD), LXRX shares are showing a performance of 13.74% which decreased to -35.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.62 but also hit the highest price of $3.73 during that period. The average intraday trading volume for Lexicon Pharmaceuticals Inc shares is 4.85 million. The stock is currently trading 8.33% above its 20-day simple moving average (SMA20), while that difference is up 1.00% for SMA50 and it goes to -45.20% lower than SMA200.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) currently have 361.49M outstanding shares and institutions hold larger chunk of about 29.69% of that.
The stock has a current market capitalization of $303.65M and its 3Y-monthly beta is at 1.05. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 7.43 while making debt-to-equity ratio of 0.59. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LXRX, volatility over the week remained 12.06% while standing at 12.29% over the month.
Analysts are in expectations that Lexicon Pharmaceuticals Inc (LXRX) stock would likely to be making an EPS of -0.12 in the current quarter, while forecast for next quarter EPS is -0.12 and it is -0.5 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.17 which is -0.08 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.2 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 14.05% while it is estimated to increase by 31.83% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 17, 2024 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by Leerink Partners stated Lexicon Pharmaceuticals Inc (LXRX) stock as an Outperform in their note to investors on April 30, 2024, suggesting a price target of $5 for the stock. On March 07, 2023, Jefferies Initiated their recommendations, while on August 12, 2022, Piper Sandler Initiated their ratings for the stock with a price target of $10. Stock get a Neutral rating from JP Morgan on January 29, 2021.
